Vδ2γδT细胞下降与肝损害通过调节Th17细胞

kaixincjx

总体来说，我对于能分享的总比不分享好，所以感谢楼主，至于好坏自己去辨别。感谢楼主，忘继续。不要受困扰。

StephenW

回复 kaixincjx 的帖子

谢谢.
   老王经常来这里学习

MP4

尹芝南,南开大学
王福生,302医院
田中義正,日本京都大学

StephenW

回复 MP4 的帖子

王福生,302医院 - 他有一个顶阅读(Top Read)2012年发表的论文:
Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection
慢性乙肝病毒感染的免疫发病机制及预后免疫标记
    Zheng Zhang,
    Ji-Yuan Zhang,
    Li-Feng Wang,
    Fu-Sheng Wang*

Journal of Gastroenterology and Hepatology

Volume 27, Issue 2, pages 223–230, February 2012

Abstract

Host immune responses induced by hepatitis B virus (HBV) infection not only substantially drive disease progression, but also significantly influence efficacy of antiviral treatments in HBV-infected individuals. Therefore, it is important to fully understand the course of immune pathogenesis and to find efficient immunological markers that can predict the disease progression of chronic HBV infection. This review introduces the current progress in clinical immunology and analyzes the mechanisms of antiviral effects and liver injury, which are induced by both innate and adaptive immune responses. The recently identified immunological markers indicated to be closely correlated with disease progression and antiviral efficacy during HBV infection are also summarized. Careful monitoring of these immune markers may help physicians to make decisions on when to begin or withdraw antiviral drugs, or to formulate the prognosis of acute-on-chronic liver failure (ACLF) patients in the clinic. Finally, this review highlights some novel therapeutic strategies to modulate host immunity that have been proposed to sustain antiviral control of chronic HBV infection, as well as the challenges that we are presently facing in the field.


主机由乙型肝炎病毒（HBV）感染引起的免疫反应，不仅大大推动疾病进展，但也显着影响HBV感染者的抗病毒治疗的疗效。因此，重要的是要充分了解免疫发病机制的过程中，找到有效的免疫学标记，可以预测慢性HBV感染疾病的进展。本文综述了目前的进展，在临床免疫学和分析机制的抗病毒效果和肝损伤，这是先天免疫和适应性免疫应答的诱导。最近发现的免疫标志表明，在HBV感染的疾病进展和抗病毒疗效密切相关，也总结。仔细监测这些免疫标记可以帮助医生做出决定何时开始或撤回抗病毒药物，或急性慢性肝衰竭（ACLF）患者在门诊制订的预后。最后，这篇评论强调了一些新的治疗策略，以调节宿主的免疫力已经被提出来维持慢性HBV感染者的抗病毒控制，以及我们目前在该领域面临的挑战。